SC-435

• UNSPSC Description:

  SC-435 is an orally effective apical sodium codependent bile acid transporter (ASBT) inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations[1] [2] [3].

• Target Antigen:

  Apical Sodium-Dependent Bile Acid Transporter

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/sc-435.html

• Purity:

  98.73

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  CS(=O)([O-])=O.O[C@@H]1[C@@](C2=CC=C(C=C2)OCCCC[N+]34CCN(CC4)CC3)([H])C5=CC(N(C)C)=CC=C5S(=O)(CC1(CCCC)CCCC)=O

• Molecular Weight:

  722.01

• References & Citations:

  [1]West KL, et, al. 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. J Pharmacol Exp Ther. 2002 Oct;303(1):293-9.|[2]Xie G, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018 Nov;37:294-306.|[3]West KL, et al. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein metabolism in guinea pigs. J Nutr Biochem. 2005 Dec;16(12):722-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  289037-67-8